Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Axiogenesis AG

Drug Development

Axiogenesis AG is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue.  Axiogenesis' technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds.
Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research in general.  Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes, neurons and other cell types, as well as drug development assays and disease models, to help researchers discover cures.
 

Details


Adresse:
Axiogenesis AG
Drug Development
Nattermannallee 1
Bldg. S20
50829 Köln
Deutschland
Arbeitsgebiet:
Forschung & Lehre
Sonstige Tätigkeitsfelder
Expansion:
international
Mitarbeiteranzahl:
11-50
Gründungsjahr:
2000